Medtronic (NYSE:MDT) Shares Unloaded Rep. Julie Johnson

Posted by Patrick Bannon on Dec 18th, 2025

Representative Julie Johnson (D-Texas) recently sold shares of Medtronic PLC (NYSE:MDT). In a filing disclosed on December 11th, the Representative disclosed that they had sold between $1,001 and $15,000 in Medtronic stock on November 13th. The trade occurred in the Representative’s “CHASE BROKERAGE ACCOUNT (3935)” account.

Representative Julie Johnson also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of Charles Schwab (NYSE:SCHW) on 11/13/2025.
Sold $1,001 – $15,000 in shares of UnitedHealth Group (NYSE:UNH) on 11/13/2025.
Sold $1,001 – $15,000 in shares of Cigna Group (NYSE:CI) on 11/13/2025.
Sold $1,001 – $15,000 in shares of Xcel Energy (NASDAQ:XEL) on 11/13/2025.
Sold $1,001 – $15,000 in shares of Capital One Financial (NYSE:COF) on 11/13/2025.
Sold $1,001 – $15,000 in shares of Walmart (NASDAQ:WMT) on 11/13/2025.
Sold $1,001 – $15,000 in shares of Seagate Technology (NASDAQ:STX) on 11/13/2025.
Sold $1,001 – $15,000 in shares of Wells Fargo & Company (NYSE:WFC) on 11/13/2025.
Sold $1,001 – $15,000 in shares of Texas Instruments (NASDAQ:TXN) on 11/13/2025.
Sold $1,001 – $15,000 in shares of The Goldman Sachs Group (NYSE:GS) on 11/13/2025.

Medtronic Stock Up 0.2%

NYSE MDT traded up $0.24 during trading on Thursday, reaching $98.54. 5,526,163 shares of the company’s stock were exchanged, compared to its average volume of 6,383,892. The stock has a market cap of $126.33 billion, a P/E ratio of 26.56, a price-to-earnings-growth ratio of 2.59 and a beta of 0.71. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.80 and a current ratio of 2.42. The company has a 50 day moving average price of $97.32 and a two-hundred day moving average price of $93.25. Medtronic PLC has a 1 year low of $79.29 and a 1 year high of $106.33.

Medtronic (NYSE:MDT – Get Free Report) last issued its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share for the quarter, topping the consensus estimate of $1.31 by $0.05. The business had revenue of $8.96 billion for the quarter, compared to analyst estimates of $8.86 billion. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The business’s quarterly revenue was up 6.6% on a year-over-year basis. During the same quarter last year, the company earned $1.26 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, equities research analysts anticipate that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 16th. Shareholders of record on Friday, December 26th will be paid a $0.71 dividend. The ex-dividend date is Friday, December 26th. This represents a $2.84 dividend on an annualized basis and a yield of 2.9%. Medtronic’s dividend payout ratio (DPR) is currently 76.55%.

Analyst Upgrades and Downgrades

MDT has been the topic of a number of research analyst reports. Truist Financial cut their price objective on shares of Medtronic from $110.00 to $107.00 and set a “hold” rating on the stock in a report on Thursday. Robert W. Baird set a $103.00 price target on shares of Medtronic in a research note on Tuesday. Piper Sandler reissued a “neutral” rating on shares of Medtronic in a research report on Friday, November 14th. Royal Bank Of Canada raised their price objective on Medtronic from $111.00 to $118.00 and gave the stock an “outperform” rating in a report on Wednesday, November 19th. Finally, Stifel Nicolaus lifted their target price on Medtronic from $90.00 to $105.00 and gave the stock a “hold” rating in a research report on Thursday, October 9th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and twelve have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $109.94.

View Our Latest Report on MDT

Institutional Investors Weigh In On Medtronic

Several hedge funds have recently made changes to their positions in the business. Advisors Management Group Inc. ADV increased its position in Medtronic by 1.4% in the 3rd quarter. Advisors Management Group Inc. ADV now owns 52,549 shares of the medical technology company’s stock valued at $5,005,000 after acquiring an additional 704 shares during the period. Hudson Bay Capital Management LP increased its holdings in shares of Medtronic by 134.5% in the third quarter. Hudson Bay Capital Management LP now owns 25,016 shares of the medical technology company’s stock valued at $2,383,000 after purchasing an additional 97,432 shares during the period. Innova Wealth Partners purchased a new stake in shares of Medtronic during the third quarter worth approximately $210,000. Tevis Investment Management raised its stake in shares of Medtronic by 1.8% during the third quarter. Tevis Investment Management now owns 53,510 shares of the medical technology company’s stock worth $5,134,000 after purchasing an additional 958 shares during the last quarter. Finally, Groupama Asset Managment lifted its holdings in shares of Medtronic by 62.9% during the third quarter. Groupama Asset Managment now owns 57,642 shares of the medical technology company’s stock worth $5,490,000 after purchasing an additional 22,255 shares during the period. Institutional investors and hedge funds own 82.06% of the company’s stock.

About Representative Johnson

Julie Johnson (Democratic Party) is a member of the U.S. House, representing Texas’ 32nd Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

Johnson (Democratic Party) ran for election to the U.S. House to represent Texas’ 32nd Congressional District. She won in the general election on November 5, 2024.

Julie Johnson earned a B.A. in history and government from the University of Texas at Austin in 1987 and a J.D. from the University of Houston Law Center in 1991. Johnson’s career experience includes working as an attorney.

About Medtronic

(Get Free Report)

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.